South Korea Govt Proposes “Refund System” To Keep MNC Drug Prices Up, Provide Access To Patients
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs is in pursuit of what it calls a "refunding system" under which multinational companies could sell their products at prices they want under the coverage of the local National Health Insurance System
You may also be interested in...
Korea Extends Closely Watched Pilot Project For Rare Disease Drug Refunds Three More Years
To maintain a stable supply of some multinational products for patients with rare diseases, the health ministry has extended its pilot refund system for three more years until 2015.
Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court
SEOUL - In what appears to be a victory - at least for now - for multinational pharma companies in their fight against mounting calls for price cuts, a Seoul Administrative Court maintained its earlier stance and ruled that a court-ordered price cut for Novartis' Glivec (imatinib) goes against "fairness" and the purpose of the EU free trade agreement
Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court
SEOUL - In what appears to be a victory - at least for now - for multinational pharma companies in their fight against mounting calls for price cuts, a Seoul Administrative Court maintained its earlier stance and ruled that a court-ordered price cut for Novartis' Glivec (imatinib) goes against "fairness" and the purpose of the EU free trade agreement